NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Real-world Experience of Catheter Ablation Using Novel Ablation Technologies for the Treatment of Atrial Fibrillation

UnknownN/A

Sponsor: Beijing Anzhen Hospital

Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation

Interventions: Catheter ablation

The primary purpose of this registry is to obtain real-world clinical experience for the latest and future ablation technologies when used in conjunction with the Carto system in the treatment of patients with atrial fibrillation (AF) in Asian countries. The ablation technologies include THERMOCOOL SMARTTOUCH® SF (STSF) catheter with Ablation Index (AI) /Visitag SURPOINT, QDOT catheter, and HELIOSTAR catheter. Additional new ablation and/or mapping technologies may be included in future when they become available in local markets.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Aged 18 years or older
* Signed informed consent to participate in the study
* Drug refractory symptomatic paroxysmal AF or symptomatic persistent AF for less than 12 months who, in the opinion of the investigator, are candidates for catheter ablation per standard-of-care
* Undergoing AF ablation for the first time
* THERMOCOOL SMARTTOUCH® SF catheter with Visitag SURPOINT or newer technologies (e.g. QDOT, HELIOSTAR) are used in conjunction with Carto system in the ablation procedure

Exclusion Criteria:

* Women of childbearing potential who are, or plan to become, pregnant during the time of the study
* The subject has a life expectancy of less than 12 months
* Severe valvular heart disease
* The subject has been enrolled in another investigational study evaluating a medical device or a drug.